Top

Published in:

Open Access 01-12-2018 | Case report

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Pneumatosis intestinalis (PI) is a rare complication of chemotherapy, characterized by multiple gas accumulations within the bowel wall.

Case presentation

A 71-year-old woman with epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma was admitted to our hospital because of reduced consciousness. She was diagnosed as having leptomeningeal carcinomatosis (LM) using lumbar puncture. Because she could not swallow a tablet, erlotinib was administered via a feeding tube. Her state of consciousness gradually improved, but she experienced diarrhea several times a day. After 3 weeks of erlotinib therapy, PI occurred. Erlotinib was discontinued and PI was resolved after treatment with conservative therapies. Erlotinib was re-administrated and PI occurred again. After improvement of erlotinib-induced PI, gefitinib was administered by a feeding tube and the patient did not experience PI or diarrhea. The patient survived 8 months from the diagnosis of LM.

Conclusion

PI is one of the side effects of erlotinib, and consecutive therapies are useful for the treatment of PI. In this patient, gefitinib was successfully administered after erlotinib-induced PI.

Shinagare AB, Howard SA, Krajewski KM, Zukotynski KA, Jagannathan JP, Ramaiya NH. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol. 2012;199(6):1259–165.CrossRefPubMed

Koreishi A, Lauwers GY, Misdraji J. Pneumatosis intestinalis: a challenging biopsy diagnosis. Am J Surg Pathol. 2007;31(10):1469–75.CrossRefPubMed

St Peter SD, Abbas MA, Kelly KA. The spectrum of pneumatosis intestinalis. Arch Surg. 2003;138(1):68–75.CrossRefPubMed

Suzuki HI, Izutsu K, Watanabe T, Oshima K, Kanda Y, Motokura T, et al. Late-onset pneumatosis cystoides intestinalis associated with non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2008;88(1):116–8.CrossRefPubMed

Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA. Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Investig New Drugs. 2008;26(1):95–6.CrossRef

Coriat R, Ropert S, Mir O, Billemont B, Chaussade S, Massault PP, et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Investig New Drugs. 2011;29(5):1090–3.CrossRef

Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Investig New Drugs. 2009;27(1):83–7.CrossRef

Jarkowski A 3rd, Hare R, Francescutti V, Wilkinson N, Khushalani N. Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor. Anticancer Res. 2011;31(10):3429–32.PubMed

Kashima T, Ohno Y, Tachibana M. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib. Int J Urol. 2012;19(11):1041–2.CrossRefPubMed

10.

Vijayakanthan N, Dhamanaskar K, Stewart L, Connolly J, Leber B, Walker I, et al. A review of pneumatosis intestinalis in the setting of systemic cancer treatments, including tyrosine kinase inhibitors. Can Assoc Radiol J. 2012;63(4):312–7.CrossRefPubMed

11.

Viswanathan C, Bhosale P, Ganeshan DM, Truong MT, Silverman P, Balachandran A. Imaging of complications of oncological therapy in the gastrointestinal system. In: Cancer Imaging. 2012;12:163–72.PubMedPubMedCentral

12.

Yoon S, Hong YS, Park SH, Lee JL, Kim TW. Pneumatosis intestinalis after cetuximab-containing chemotherapy for colorectal cancer. Jpn J Clin Oncol. 2011;41(10):1225–8.CrossRefPubMed

13.

Iwasaku M, Yoshioka H, Korogi Y, Kunimasa K, Nishiyama A, Nagai H, et al. Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma. J Thorac Oncol. 2012;7(1):257.CrossRefPubMed

14.

Lee JY, Han HS, Lim SN, Shim YK, Choi YH, Lee OJ, et al. Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma. BMC Cancer. 2012;12:87.CrossRefPubMedPubMedCentral

15.

Hughes B, Mileshkin L, Townley P, Gitlitz B, Eaton K, Mitchell P, et al. Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. Oncologist. 2014;19(2):175–6.CrossRefPubMedPubMedCentral

16.

Ando T, Sakata J, Maruyama T, Hirose Y, Okabe Y, Takizawa K, et al. A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma. Gan To Kagaku Ryoho. 2015;42(7):847–9. Abstract in EnglishPubMed

17.

Maeda A, Nakata M, Shimizu K, Yukawa T, Saisho S, Okita R. Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report. World J Surg Oncol. 2016;14(1):175.CrossRefPubMedPubMedCentral

18.

Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2015;88(1):74–9.CrossRefPubMed

19.

Chang SC, Chang CY, Chen CY, Yu CJ. Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol. 2010;5(7):1105–6.CrossRefPubMed

20.

Takeda M, Okamoto I, Makimura C, Fukuoka M, Nakagawa K. Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. J Thorac Oncol. 2010;5(7):1103–4.CrossRefPubMed

21.

Koma Y, Matsuoka H, Yoshimatsu H, Suzuki Y. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review. Int J Clin Pharmacol Ther. 2012;50(10):760–4.CrossRefPubMed

22.

Kashiwabara K, Semba H, Fujii S, Tsumura S. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Cancer Chemother Pharmacol. 2017;79(4):705–10.CrossRefPubMed

23.

Wolfe JN, Evans WA. Gas in the portal veins of the liver in infants; a roentgenographic demonstration with postmortem anatomical correlation. Am J Roentgenol Radium Therapy, Nucl Med. 1955;74(3):486–8.

24.

Lassandro F, Valente T, Rea G, Lassandro G, Golia E, Brunese L, et al. Imaging assessment and clinical significance of pneumatosis in adult patients. Radiol Med. 2015;120(1):96–104.CrossRefPubMed

25.

Sakurai Y, Hikichi M, Isogaki J, Furuta S, Sunagawa R, Inaba K, et al. Pneumatosis cystoides intestinalis associated with massive free air mimicking perforated diffuse peritonitis. World J Gastroenterol. 2008;14(43):6753–6.CrossRefPubMedPubMedCentral

26.

Aziret M, Erdem H, Ulgen Y, Kahramanca S, Cetinkunar S, Bozkurt H, et al. The appearance of free-air in the abdomen with related pneumatosis cystoides intestinalis: three case reports and review of the literature. Int J Surg Case Rep. 2014;5(12):909–13.CrossRefPubMedPubMedCentral

27.

Honne K, Maruyama A, Onishi S, Nagashima T, Minota S. Simultaneous pneumatosis cystoides intestinalis and pneumomediastinum in a patient with systemic sclerosis. J Rheumatol. 2010;37(10):2194–5.CrossRefPubMed

28.

Keklik F, Cayci Z, Arndt P, Ustun C. Spontaneous complete resolution of pneumomediastinum and pneumatosis intestinalis caused by acute GVHD. Am J Hematol. 2016;91(7):749–50.CrossRefPubMed

Title: Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
Publication date: 01-12-2018
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4743-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer

Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report

Semaphorin-5A maintains epithelial phenotype of malignant pancreatic cancer cells

Angiopoietin-like 4 promotes osteosarcoma cell proliferation and migration and stimulates osteoclastogenesis

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer